A Brief Review on Floating Drug Delivery System

Arora Divya*, Kumar Lalitb, Joshi Ashishc, Chaudhary Abhishekd, Devi Poojaa

*Department of pharmaceutical Chemistry, School of Pharmacy, Abhilashi University, Mandi, HP, India, Pin: 175028
bBaddi University of Emerging Sciences and Technology, Makhmujara, Baddi, Distt., Baddi Solan, Himachal Pradesh 173205, India
cABESIT, College of Pharmacy, Campus 2, 19th Km Stone, NH-09, Ghaziabad, Uttar Pradesh 201009, India

INTRODUCTION

The solid unit compressed dosage type of medication (API)/excipients is known as a tablet. For systemic intervention, oral administration is the most appropriate and widely used drug delivery method. In the pharmaceutical business, oral controlled release drug delivery has lately acquired favour as a way of attaining increased therapeutic advantages such as simplicity of dosage administration, patient compliance, and formulation flexibility. Drugs that are locally active in the stomach, predominantly absorbed from the stomach and upper portion of the GIT, are unstable in the intestinal or colonic region, disturb typical colonic flora, and have limited solubility at high pH levels are of particular interest. Mucoadhesive systems that promote adhesion to the stomach mucosa, floating systems, swelling and expanding systems, modified-shape systems, high density systems, and other delayed gastric emptying devices may all aid in regulating solid dose types' gastric retention. Forms of gastroretentive dose may extend drug retention time in the stomach, allowing them to stay in the stomach for several hours. When a drug is held for a longer amount of time in the stomach, it improves gastric retention bioavailability, increases drug solubility, and minimizes drug waste, particularly in the case of drugs that are less soluble at high pH. Gastroretentive dosage form to improve therapeutic activity availability and provide significant benefits of new drugs. A tablet is a solid pharmaceutical dosage form made consisting of a powdered mixture of active substances and excipients that has been crushed or compressed into a solid form. Tablets are one of the most commonly used medicines in the World. Almost any drug molecule can be formulated into a tablet, and the tablet manufacturing process is very straightforward.1,2

Types of Compressed Tablets

Compression of powdered, crystalline, or granular active materials (API), alone or in conjunction with excipients such as binders, disintegrants, sustained release polymers, lubricants, diluents, flavours, and colourants, is used to create the tablets.

1. Sugar Coated Tablets (SCT)
2. Film Coated Tablets (FCT)
3. Enteric-Coated Tablets (ECT)
4. Multi Compressed Tablets (MCT): These are compressed Tablets made by more than one compression cycle.
5. Layered Tablets
6. Press Coated Tablets
7. Sustained Release Tablets
8. Tablets for Solution
9. Effervescent Tablets
10. Compressed Suppositories or Inserts
11. Buccal and Sublingual Tablets
Sustained release tablets
Managed release, extended release, and depot release are all terms used to describe how long anything lasts after it is released. These are the many terms used to describe drug delivery systems that are designed to provide a long-term therapeutic impact by continuously releasing medicine after a single dosage of medication has been delivered. The goal of creating sustained release delivery systems is to reduce dosage frequency while also increasing medication efficacy by localizing the drug at the site of action, decreasing the amount required, and guaranteeing uniform drug administration. The optimal medication delivery system will require two things: first, a single dosage for the duration of therapy, whether it is for days or weeks, as in the case of an infection, or for the rest of the patient’s life, as in the case of hypertension or diabetes. Second, it can carry the active ingredient directly to the action site, reducing side effects.

FLOATING DRUG DELIVERY SYSTEM
Floating systems, also known as hydrodynamically driven systems, are low-density systems with enough buoyancy to float over gastric contents and remain buoyant in the stomach for an extended period of time without affecting the gastric emptying rate. The drug is slowly released at the optimal rate from the system while it is floating on the gastric contents. The residual solid in the stomach is emptied after the medication is released. As a consequence, GRT is improved, and variations in plasma drug concentration are better regulated. A minimum amount of floating force (F) is also necessary to keep the dosage type in the stomach and stay there. The floating force (F) is also necessary to keep the dosage type in the stomach and stay there. The floating force (F) is also necessary to keep the dosage type in the stomach and stay there. The floating force (F) is also necessary to keep the dosage type in the stomach and stay there.

Swellable polymers like hydroxypropyl methylcellulose, polysaccharides, and chitosan, as well as several effervescent materials like sodium bicarbonate, calcium carbonate, citric acid, or tartaric acid, are used to make these effervescent Floating Drug Delivery System targets the process of polymer swelling and polymer bioadhesion to the GI tract’s mucosal layer. Gel forming or swellable type hydrocolloids, polysaccharides, and matrix forming polymers like polymethacrylates, polycarbonates, polyacrylates, polystyrenes, and bioadhesion polymers like chitosan and carbopol are the most widely used excipients for the preparation of non-effervescent FDDS. One method for creating floating dosage forms is to thoroughly combine the medication with the hydrocolloids that shape the gel. As the dosage type comes into contact with gastric juices, it swells up and forms a gelatinous barrier on the surface.

DISADVANTAGES OF FDDS
1. Drugs that aren’t soluble in gastric fluids aren’t good candidates for floating drug delivery systems.
2. Drugs that go through a lot of first-pass metabolism aren’t good candidates for a floating drug delivery device. Nifedipine is a good example. Nifedipine is well absorbed in the GI tract, but it may not be ideal for FDDS due to the sluggish gastric emptying, which may result in decreased systemic bioavailability. There are also limits to the use of FDDS for medications that irritate the gastric mucosa.
3. The stomach needs a large amount of fluid to float the drug in the floating drug delivery system.
4. Due to the presence of food, the floating drug delivery mechanism will cause a pause in gastric emptying.
5. The presence of food is often needed for these systems to postpone gastric emptying.

CLASSIFICATION OF FLOATING DRUG DELIVERY SYSTEMS
1. Effervescent FDDS
2. Non-effervescent FDDS

Effervescent Floating Drug Delivery System

Non-effervescent Floating Drug Delivery System

APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEMS
1. Enhanced bioavailability: In comparison to non-GRDF CR polymeric formulations, riboflavin CR-GRDF has a much greater bioavailability. There are many mechanisms that function in concert to affect the degree of drug absorption, including drug absorption and transit in the gastrointestinal tract.
2. Sustained drug delivery: Problems with gastric residence time in the GIT have been recorded with oral CR formulations. These issues can be solved using HBS systems, which can stay in the stomach for long periods of time and have a bulk density that allows them to float on top of the gastric contents. These devices are larger in scale, and they are not permitted to move through the pyloric opening.
3. **Site-specific drug delivery systems**: These systems are especially useful for medications that are absorbed primarily through the stomach or the proximal small intestine. The monitored, gradual delivery of the medication to the colon ensures adequate local therapeutic levels while limiting the drug’s systemic exposure. The drug’s side effects in the blood supply are minimised as a result. Furthermore, a site guided delivery system’s prolonged gastric availability can reduce dosing frequency. Furosemide and riboflavin are two examples.

4. **Absorption enhancement**: Drugs with low bioavailability due to site-specific absorption from the upper part of the GIT may be formulated as floating drug delivery systems to increase absorption.

5. **Minimized adverse activity at the colon**: The amount of drug that enters the colon is reduced when the drug is retained in the HBS systems at the stomach. As a result, the drug’s undesirable effects in the colon can be avoided. The justification for GRDF formulation for beta-lactam antibiotics that are absorbed only from the small intestine and whose presence in the colon contributes to the production of microorganism resistance is based on this pharmacodynamic aspect.

6. **Reduced fluctuations of drug concentration**: In comparison to immediate release dosage types, continuous input of the medication after CRGRDF administration provides blood drug concentrations within a narrower range. As a result, drug effect variations are reduced, and concentration-dependent adverse effects associated with peak doses can be avoided. This is particularly important for drugs with a limited therapeutic index.

**CONCLUSIONS**

FDDS approach may be used for active pharmaceuticals agents with narrow absorption window, or drug which are absorbed from GI tract or cause burning sensation in the stomach. This drug development pharmaceutical technology is used to reduce to fluctuation of drug concentrate. In oral solid dosages form it is FDDS is best for formulation and optimization of sustained released tablet for those active pharmaceuticals ingredients not show the first pass metabolism. We are so close to see a greater transition of FDDS developmental to the manufacturing and commercial level.

**ACKNOWLEDGEMENT**

We would like to thank all the faculty of School of Pharmacy, Abhilashi University, Baddi University of Emerging Sciences and Technology and ABESIT College of Pharmacy for their constant support.

**REFERENCES**


